What is the next step in management for a patient on full‑dose Janumet (metformin 1000 mg twice daily plus sitagliptin 100 mg daily) and Forxiga (dapagliflozin 10 mg daily) whose A1c is not at target?

Add a GLP-1 Receptor Agonist

The next step is to add a GLP-1 receptor agonist (GLP-1 RA) or dual GIP/GLP-1 RA to the current regimen, as this patient has failed triple oral therapy and requires intensification with a more potent glucose-lowering agent. 1

Rationale for GLP-1 RA Addition

The 2025 ADA Standards of Care explicitly state that when A1C remains above goal on current therapy, treatment intensification should not be delayed 1. Your patient is on:

• Metformin (1000 mg twice daily via Janumet)
• Sitagliptin (DPP-4 inhibitor, 100 mg daily via Janumet)
• Dapagliflozin (SGLT2 inhibitor, 10 mg daily via Forxiga)

This represents maximal oral triple therapy. The guidelines are clear that adding a GLP-1 RA typically lowers A1C by 1-2% when added to metformin 1, which is substantially more potent than adding another oral agent.

Why Not Continue DPP-4 Inhibitor

You must discontinue the sitagliptin (Janumet component) when starting a GLP-1 RA. The 2025 ADA guidelines explicitly state: "We do not recommend using GLP-1 RAs (or the dual GIP and GLP-1 RA) together with a DPP-4 inhibitor as there is no added glucose-lowering benefit beyond that of the GLP-1 RA alone" 1. Both drug classes work through incretin pathways, making concurrent use redundant and wasteful.

Practical Implementation

Switch from Janumet to plain metformin (1000 mg twice daily or 2000 mg extended-release once daily) and continue Forxiga (dapagliflozin 10 mg daily). Then add:

• Semaglutide (Ozempic 0.25 mg weekly, titrate to 0.5-1 mg weekly, or up to 2 mg if needed)
• Dulaglutide (Trulicity 0.75-1.5 mg weekly, can increase to 3-4.5 mg)
• Tirzepatide (Mounjaro 2.5 mg weekly, titrate up to 15 mg) - the dual GIP/GLP-1 RA with superior A1C reduction

If cardiovascular disease or high CV risk is present, prioritize semaglutide or dulaglutide as they have proven cardiovascular outcome benefits 2, 1.

Supporting Evidence from Research

Multiple recent trials demonstrate superior efficacy of triple therapy including SGLT2i + DPP-4i + metformin versus dual combinations 3, 4, 5. However, GLP-1 RAs are more potent than DPP-4 inhibitors for glucose lowering and provide additional benefits:

• Greater A1C reduction (1-2% vs 0.7-1.0% for oral agents) 1
• Significant weight loss (not achieved with DPP-4 inhibitors)
• Cardiovascular and renal protection in high-risk patients 2
• Lower hypoglycemia risk compared to insulin

When to Consider Insulin Instead

Consider basal insulin if 1:

• A1C >10% or blood glucose ≥300 mg/dL
• Symptomatic hyperglycemia (polyuria, polydipsia, weight loss)
• Catabolic features present

If none of these apply, GLP-1 RA is preferred over insulin because it avoids hypoglycemia risk and weight gain while providing comparable or superior A1C reduction 1.

Common Pitfalls to Avoid

1. Do not continue sitagliptin with GLP-1 RA - this is explicitly contraindicated and provides no benefit 1
2. Do not delay intensification - therapeutic inertia worsens long-term outcomes 1
3. Do not add another oral agent - you've maximized oral therapy; injectable therapy is needed for adequate A1C reduction 1
4. Maintain the SGLT2 inhibitor (dapagliflozin) - it provides independent cardiovascular and renal benefits beyond glucose lowering 2

Reassessment Timeline

Evaluate response in 3 months 1. If A1C remains above goal on GLP-1 RA + metformin + SGLT2i, then consider adding basal insulin (can use fixed-ratio combination products like iGlarLixi or IDegLira if appropriate) 1.